5 research outputs found
ΠΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π±Π°ΠΊΡΠ΅ΡΠΈΠΎΡΠ°Π³ΠΎΠ² Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ: ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΎΠ±Π·ΠΎΡ
Successful implementation of lytic virulent bacteriophages in clinical practice requires convincing evidence of its safety and efficacy.Design: We searched in CENTRAL, MEDLINE, Embase, and Russian-language literature databases in May 2018. Original articles must fulfill the following eligibility criteria: randomized, controlled trials investigating the effects of phage therapy in people with bacterial infections; at least one patient outcome was reported. Three review authors independently selected, studies, extracted, data, and. assessed, risk of bias. We used, random-effects models for meta-analysis.Participants: adults and. children of both, sexes with bacterial infection, including multi-drug resistant variants, or individuals at risk of infection.Outcomes: recovery or resolution of infection; clinical improvement; change in number of exacerbations; recurrence of infection; quality of life; elimination or load, reduction of a pathogen in an anatomical compartment.Results: We included 13 trials (issued in 1965-2018) including 9 treatment studies and. 4 prevention studies. Overall, eight randomized, trials involved, adults. Five studies addressed skin and soft tissues infections, six studies concerned intestinal infections, one study addressed respiratory tract infection and. one study β ear infection. Across bias domains, 35-90% of trials scored, low risk of bias. Meta-analysis for adverse events attributable to phages and. for wound, healing provided us with pooled relative risks of 0.74 (95% CI 0.68;1.2) and 0.91 (95% CI0.68;1.2) respectively.Conclusions: Beneficial effect of bacteriophages can be demonstrated, and. not refuted. However, our study led. to tentative conclusions. The conduct of well-designed and sufficiently powered, trials would, facilitate registration and. wide accepting of bacteriophage treatment.Π¦Π΅Π»Ρ: ΠΎΡΠ΅Π½ΠΊΠ° ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π±Π°ΠΊΡΠ΅ΡΠΈΠΎΡΠ°Π³ΠΎΠ², ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΡΡ
Π΄Π»Ρ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΈΠ»ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Π±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΡΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ Ρ Π»ΡΠ΄Π΅ΠΉ.ΠΠ΅ΡΠΎΠ΄: ΠΏΠΎΠΈΡΠΊ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ Π² Π°Π½Π³Π»ΠΎ- ΠΈ ΡΡΡΡΠΊΠΎΡΠ·ΡΡΠ½ΡΡ
Π±Π°Π·Π°Ρ
Π΄Π°Π½Π½ΡΡ
Π² 2018 Π³. ΠΡΠΈΡΠ΅ΡΠΈΠΈ ΠΎΡΠ±ΠΎΡΠ° ΠΎΡΠΈΠ³ΠΈΠ½Π°Π»ΡΠ½ΡΡ
ΡΡΠ°ΡΠ΅ΠΉ: ΡΠ°Π½Π΄ΠΎΠΌΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΊΠΎΠ½ΡΡΠΎΠ»ΠΈΡΡΠ΅ΠΌΡΠ΅ ΠΈΡΠΏΡΡΠ°Π½ΠΈΡ; ΠΎΠΏΠΈΡΠ°Π½ ΠΊΠ°ΠΊ ΠΌΠΈΠ½ΠΈΠΌΡΠΌ, ΠΎΠ΄ΠΈΠ½ ΠΈΡΡ
ΠΎΠ΄, Π·Π½Π°ΡΠΈΠΌΡΠΉ Π΄Π»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°; Π²Π·ΡΠΎΡΠ»ΡΠ΅ ΠΈ Π΄Π΅ΡΠΈ, ΠΎΠ±ΠΎΠ΅Π³ΠΎ ΠΏΠΎΠ»Π°, Ρ Π΄ΠΈΠ°Π³Π½ΠΎΠ·ΠΎΠΌ Π±Π°ΠΊΡΠ΅ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ ΠΈΠ»ΠΈ Π»ΠΈΡΠ° Ρ ΡΠΈΡΠΊΠΎΠΌ, Π·Π°ΡΠ°ΠΆΠ΅Π½ΠΈΡ. Π’ΡΠΈ Π°Π²ΡΠΎΡΠ° Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΠΎ Π΄ΡΡΠ³ ΠΎΡ Π΄ΡΡΠ³Π° ΠΎΡΠ±ΠΈΡΠ°Π»ΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ, ΠΈΠ·Π²Π»Π΅ΠΊΠ°Π»ΠΈ Π΄Π°Π½Π½ΡΠ΅ ΠΈ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΡΠΈΡΠΊ ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΡΠΈΠ±ΠΊΠΈ. ΠΠ»Ρ ΠΌΠ΅ΡΠ°-Π°Π½Π°Π»ΠΈΠ·Π° ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½Π° ΠΌΠΎΠ΄Π΅Π»Ρ ΡΠ»ΡΡΠ°ΠΉΠ½ΡΡ
ΡΡΡΠ΅ΠΊΡΠΎΠ². ΠΡΡ
ΠΎΠ΄Ρ: Π²ΡΠ·Π΄ΠΎΡΠΎΠ²Π»Π΅Π½ΠΈΠ΅; ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΡΠ»ΡΡΡΠ΅Π½ΠΈΠ΅; ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΠΈΡΠ»Π° ΠΎΠ±ΠΎΡΡΡΠ΅Π½ΠΈΠΉ; ΡΠ΅ΡΠΈΠ΄ΠΈΠ² ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ; ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΠΆΠΈΠ·Π½ΠΈ; ΡΠ»ΠΈΠΌΠΈΠ½Π°ΡΠΈΠΈ ΠΈΠ»ΠΈ ΡΠΌΠ΅Π½ΡΡΠ΅Π½ΠΈΠ΅ Π½Π°Π³ΡΡΠ·ΠΊΠΈ ΠΏΠ°ΡΠΎΠ³Π΅Π½Π° Π² Π°Π½Π°ΡΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠΌ, Π»ΠΎΠΊΡΡΠ΅.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΠΏΠΎΡΠ»Π΅ ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΡΠ΅Π½ΠΊΠΈ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ, ΠΌΡ. Π²ΠΊΠ»ΡΡΠΈΠ»ΠΈ 13 ΠΏΡΠ±Π»ΠΈΠΊΠ°ΡΠΈΠΉ: ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π»Π΅ΡΠ΅Π½ΠΈΡ (n = 9) ΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ (ΠΏ = 4). ΠΠ· Π½ΠΈΡ
5 ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π±ΡΠ»ΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Ρ, Π² Π ΠΎΡΡΠΈΠΈ ΠΈ Π±ΡΠ²ΡΠ΅ΠΌ. Π‘Π‘Π‘Π , 3 β Π² Π‘Π¨Π, 2 β Π² ΠΠ°ΠΏΠ°Π΄Π½ΠΎΠΉ ΠΠ²ΡΠΎΠΏΠ΅, 2βΠ² ΠΠ·ΠΈΠΈ. 8 ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π±ΡΠ»ΠΎ Ρ ΡΡΠ°ΡΡΠΈΠ΅ΠΌ Π²Π·ΡΠΎΡΠ»ΡΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². 5 ΡΠ°Π±ΠΎΡ ΠΊΠ°ΡΠ°Π»ΠΈΡΡ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ ΠΊΠΎΠΆΠΈ ΠΈ ΠΌΡΠ³ΠΊΠΈΡ
ΡΠΊΠ°Π½Π΅ΠΉ, 6 β ΠΊΠΈΡΠ΅ΡΠ½ΡΡ
ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ, 1 β ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π΄ΡΡ
Π°ΡΠ΅Π»ΡΠ½ΡΡ
ΠΏΡΡΠ΅ΠΉ, 1 β Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΡΡ
Π°. ΠΠΊΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»ΠΈ ΠΎΠΏΡΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Ρ, Π² 1965β2018 Π³Π³. ΠΠΎ Π²ΡΠ΅ΠΌ, Π²ΠΈΠ΄Π°ΠΌ, ΡΠΈΡΡΠ΅ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΡΠΈΠ±ΠΊΠΈ 35β90% Π ΠΠ ΠΈΠΌΠ΅Π»ΠΈ Π½ΠΈΠ·ΠΊΠΈΠΉ ΡΠΈΡΠΊ. ΠΠ΅ΡΠ°-Π°Π½Π°Π»ΠΈΠ· Π±ΡΠ» Π²ΠΎΠ·ΠΌΠΎΠΆΠ΅Π½ ΡΠΎΠ»ΡΠΊΠΎ Π΄Π»Ρ ΠΏΠΎΠ±ΠΎΡΠ½ΡΡ
ΡΠ²Π»Π΅Π½ΠΈΠΉ, ΡΠ²ΡΠ·Π°Π½Π½ΡΡ
Ρ ΡΠ°Π³Π°ΠΌΠΈ, ΠΈ Π΄Π»Ρ Π·Π°ΠΆΠΈΠ²Π»Π΅Π½ΠΈΡ ΡΠ°Π½: 0,74 (95% ΠΠ 0,68β1,2) ΠΈ 0,91 (95% ΠΠ 0,68β1,2) ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ.ΠΡΠ²ΠΎΠ΄Ρ: Ρ ΡΡΠ΅ΡΠΎΠΌ, ΡΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π²ΡΠ΅ΠΉΡΡ Π΄ΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠ½ΠΎΠΉ Π±Π°Π·Ρ, Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΉ ΡΡΡΠ΅ΠΊΡ ΡΠ°Π³ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π½Π΅ Π²ΡΠ·ΡΠ²Π°Π΅Ρ ΡΠΎΠΌΠ½Π΅Π½ΠΈΠΉ. ΠΠ΄Π½Π°ΠΊΠΎ Π½Π°ΡΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠ΄Π΅Π»Π°ΡΡ Π»ΠΈΡΡ ΠΏΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ Π²ΡΠ²ΠΎΠ΄Ρ. Π¨ΠΈΡΠΎΠΊΠΎΠ΅ ΠΏΡΠΈΠ·Π½Π°Π½ΠΈΠ΅ Π±Π°ΠΊΡΠ΅ΡΠΈΠΎΡΠ°Π³ΠΎΠ² ΠΌΠΈΡΠΎΠ²ΠΎΠΉ Π½Π°ΡΠΊΠΎΠΉ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΡΡΠ΅Π±ΡΠ΅Ρ, ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ Π ΠΠ Π΄ΠΎΠ»ΠΆΠ½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΊΠ°ΡΠ΅ΡΡΠ²Π° ΠΈ ΠΌΠΎΡΠ½ΠΎΡΡΠΈ
EPIDEMIOLOGY OPPORTUNISTIC MYCOSES
The review touches upon a problem of coinfection caused by several important fungal infections (aspergillus, candida, pneumocystis, cryptococcus) and infectious or parasitic diseases. The authors also investigate epidemiologic determinants of such clinical forms of pathologic process. There are a lot of scientific gaps in the studying coinfections concerning mycosis and other infections. Physicians and infection control practitioners sometimes reveal such cases therefore complex characteristics of the coinfections is required
GENERAL CHARACTERISTICS AND ISSUES MIXED INFECTIONS CAUSED BY OPPORTUNISTIC MICROORGANISMS
Infections caused by opportunistic microorganisms occupy a special position. In microbial associations of opportunistic microorganisms is easier to implement its low pathogenic potential, activate properties of each other. Group polyetiologic infections caused by conditionally pathogenic microorganisms are quite diverse in terms of a nosological forms and groups. These include the so-called septic infection, which are also very diverse and clinical, epidemiological and etiological characteristics. Scientific evidence shows the urgency of the problem mixed infections, especially in surgery and indicate a lack of systematic data about the whole spectrum and the composition of microbial associations in different infections, quantification, insufficient study of the properties compared to monoagents. The problem mixed infections practically not been studied with epidemiologic standpoint, only a few studies devoted to the study of nosocomial infection of microbial associations are not developed microbiological monitoring. In this connection, you need comprehensive research mixed infections compared with monoagents to identify the characteristics and development of epidemiologic surveillance and control
Efficiency of phage therapy in humans: systematic review
Successful implementation of lytic virulent bacteriophages in clinical practice requires convincing evidence of its safety and efficacy.Design: We searched in CENTRAL, MEDLINE, Embase, and Russian-language literature databases in May 2018. Original articles must fulfill the following eligibility criteria: randomized, controlled trials investigating the effects of phage therapy in people with bacterial infections; at least one patient outcome was reported. Three review authors independently selected, studies, extracted, data, and. assessed, risk of bias. We used, random-effects models for meta-analysis.Participants: adults and. children of both, sexes with bacterial infection, including multi-drug resistant variants, or individuals at risk of infection.Outcomes: recovery or resolution of infection; clinical improvement; change in number of exacerbations; recurrence of infection; quality of life; elimination or load, reduction of a pathogen in an anatomical compartment.Results: We included 13 trials (issued in 1965-2018) including 9 treatment studies and. 4 prevention studies. Overall, eight randomized, trials involved, adults. Five studies addressed skin and soft tissues infections, six studies concerned intestinal infections, one study addressed respiratory tract infection and. one study β ear infection. Across bias domains, 35-90% of trials scored, low risk of bias. Meta-analysis for adverse events attributable to phages and. for wound, healing provided us with pooled relative risks of 0.74 (95% CI 0.68;1.2) and 0.91 (95% CI0.68;1.2) respectively.Conclusions: Beneficial effect of bacteriophages can be demonstrated, and. not refuted. However, our study led. to tentative conclusions. The conduct of well-designed and sufficiently powered, trials would, facilitate registration and. wide accepting of bacteriophage treatment